Salvage cytoreductive surgery for recurrent endometrial cancer

Gynecologic Oncology

Volumn 103, Issue 1, 2006, Pages 281-287

  Bristow, Robert E ^a   Santillan, Antonio ^a   Zahurak, Marianna L ^a   Gardner, Ginger J ^a   Giuntoli II, Robert L ^a   Armstrong, Deborah K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cytoreductive surgery; Endometrial cancer; Recurrence

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLOOD COMPONENT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL RECORD; MINIMAL RESIDUAL DISEASE; MORBIDITY; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT INDICATION; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 33748566346     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.03.011     Document Type: Article

References (35)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics 2005. CA J. Clin. 55 (2005) 10-30
2. Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 40 (1991) 55-65
3. Morris M., Alvarez R.D., Kinney W.K., and Wilson T.O. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol. Oncol. 60 (1996) 288-291
4. Barakat R.R., Goldman N.A., Patel D.A., Venkatraman E.S., and Curtin J.P. Pelvic exenteration for recurrent endometrial cancer. Gynecol. Oncol. 75 (1999) 99-102
5. Chi D.S., Welshinger M., Venkatraman E.S., and Barakat R.R. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol. Oncol. 67 (1997) 56-60
6. Bristow R.E., Zerbe M.J., Rosenshein N.B., Grumbine F.C., and Montz F.J. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol. Oncol. 78 (2000) 85-91
7. Bristow R.E., Zahurak M.L., Alexander C.J., Zellars R.C., and Montz F.J. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int. J. Gynecol. Cancer 13 (2003) 664-672
8. Lambrou N.C., Gomez-Marin O., Mirhashemi R., Beach H., Salom E., Almeida-Parra Z., et al. Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol. Oncol. 93 (2004) 653-658
9. Ayhan A., Taskiran C., Celik C., Yuce K., and Kucukali T. The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. Int. J. Gynecol. Cancer 12 (2002) 448-453
10. Aalders J.G., Abeler V., and Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol. Oncol. 17 (1984) 85-103
11. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-480
12. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22 (1959) 719-748
13. Cox D.R. Regression models and life tables. [with discussion]. J. R. Stat. Soc. 34 (1972) 187-220
14. Cox D.R. The analysis of binary data (1970), Methuen, London
15. SAS Institute Inc. SAS user's guide: statistics. Version 5. Cary NC, NC. SAS Institute Inc. 1985.
16. Statistics and epidemiology Research Corporation. EGRET user's manual. Seattle, 1988.
17. Curran W.J., Whittington R., Peters A.J., and Fanning J. Vaginal recurrences of endometrial carcinoma: the prognostic value of staging by a primary vaginal carcinoma system. Int. J. Radiat. Oncol. Biol. Phys. 15 (1988) 803-808
18. Sears J., Greven K., Hoen H.M., and Randall M.E. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer 74 (1994) 1303-1308
19. Wylie J., Irwin C., Pintilie M., Levin W., Manchul L., Milosevic M., et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol. Oncol. 77 (2000) 66-72
20. Wadler S., Levy D.E., Lincoln S.T., Soori G.S., Schink J.C., and Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group study E3E93. J. Clin. Oncol. 21 (2003) 2110-2114
21. Lincoln S., Blessing J.A., Lee R.B., and Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88 (2003) 277-281
22. Burke T.W., Munkarah A., Kavanagh J.J., Morris M., Levenback C., Tornos C., et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol. Oncol. 51 (1993) 397-400
23. Thigpen J.T., Blessing J.A., Homesley H., Creasman W.T., and Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced ore recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 33 (1989) 68-70
24. Quinn M.A., Cauchi M., and Fortune D. Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol. Oncol. 21 (1985) 314-319
25. Podratz K.C., O'Brien P.C., Malkasian Jr. G.D., Decker D.G., Jeffries J.A., and Edmonson J.H. Effects of progestational agents in treatment of endometrial carcinoma. Obstet. Gynecol. 66 (1985) 106-110
26. Piver M.S., Barlow J.J., Lurain J.R., and Blumenson L.E. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial carcinoma. Cancer 45 (1980) 268-272
27. Thigpen T., Brady M.F., Homesley H.D., Soper J.T., and Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 19 (2001) 364-367
28. Asbury R.F., Brunetto V.L., Lee R.B., Reid G., and Rocereto T.F. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am. J. Clin. Oncol. 25 (2002) 557-560
29. Goff B.A., Goodman A., Muntz H.G., Fuller A.F., Nikrui N., and Rice L.W. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol. Oncol. 52 (1994) 237-240
30. Greer B.E., and Hamberger A.D. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving strip technique and pelvic boost irradiation. Gynecol. Oncol. 16 (1983) 365-373
31. Rose P.G., Cha S.D., Tak W.K., Fitzgerald T., Reale F., and Hunter R.E. Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 24 (1992) 229-233
32. Corn B.W., Lanciano R.M., Greven K.M., Schultz D.J., Reisinger S.A., Stafford P.M., et al. Endometrial cancer with para-aortic adenopathy: patterns of failure and opportunities for cure. Int. J. Radiat. Oncol. Biol. Phys. 24 (1992) 223-227
33. Scarabelli C., Campagnutta E., Giorda G., DePiero G., Sopracordevole F., Quaranta M., et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecol. Oncol. 70 (1998) 90-93
34. Campagnutta E., Giorda G., DePiero G., Sopracordevole F., Visentin M.C., Martella L., et al. Surgical treatment of recurrent endometrial carcinoma. Cancer 100 (2004) 89-96
35. Awtrey CS, Cadungog MG, Leitao MM, Alektiar K, Aghajanian C, Barakat RR, Chi DS. Surgical resection of recurrent endometrial carcinoma. The Annual Meeting on Women's Cancer 2005; Abstract 22.